Slide 1: Q1 2024 results presentation
January 2024 – March 2024– Q1 2024 results presentation
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "beli
Slide 3: Agenda
Agenda Q1 in short Business updates Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q1 in short
Q1 in short Q1 Q2 Q3 Q4 44
Slide 5: Strong start to the year with record revenue and positive cash flow
The Group has started the financial year strongly recording record revenue and generating a positive cash-flow 10% 23% €0.1m 26% Quarterly Subscription Q1 2024 cash flow Adjusted EBITDA YTD revenue growth Revenue growth positive increased to €16.3m €10.5m Extended Santander facility for a further fi
Slide 6: Business updates
Business updates Q1 Q2 Q3 Q4 6 6
Slide 7: Our two business lines: Lifecare and Wellness
Our two business lines have us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges Q@= Mental Wellbeing ‘Your Results mel sn wo ae then nd ae =I Lifecare Wellness Seamless and One platform, All Efficient care areas of employee Solutions wellbeing
Slide 8: Lifecare quarterly developments
Lifecare quarterly developments Q1 Highlights: • User base and subscription revenue of the platform continue to grow quarterly (23% year on 19% growth in license numbers within year), as we laser-focus on subscription revenue growth. Lifecare • The launch of groundbreaking features for our customers
Slide 9: Wellness quarterly developments
Wellness quarterly developments 1.6 YTD revenue, Wellness segment Q1 Highlights: 1.5 • We have made significant progress in consolidating the Wellness division, with the 11% quarterly results exclusively reflecting organic growth. 1.5 • Champion Health, while putting final touches to its new version
Slide 10: Saying hello to our growth team
Saying hello to our growth team • The way customers approach software vendors, the speed at which they interact and the level of perfection they expect has changed dramatically, especially since AI stepped on the scene in a big way in 2023. • A company that is serious about meeting these expectation
Slide 11: Financial Results
Financial Results Q1 Q2 Q3 Q4 11 1
Slide 12: Q1 Financial Highlights
Q 1 2 Q1 Financial Highlights 3 month revenue 3 Month EBITDA 10% 32% €4.1m (Q1 2023: €3.7m) €1.0m (Q1 2023: €0.7m) 3 month subscription revenue 3 Month cashflow 23% 379% €3.3m / 80% €0.9m (Q1 2023: €0.2m) (Q1 2024: €2.7m / 72%) 3 month adjusted EBITDA 3 month adjusted EBITDA margin 14% +1pp €1.1m (Q
Slide 13: Maintaining revenue growth
Q 1 2 Maintaining revenue growth Group Revenue 4.5 Lifecare revenue growth Wellness revenue growth 3.0 2.5 10% 4.0 10% 2.5 2.0 3.5 3.0 2.0 11% 1.5 2.5 1.5 2.0 1.0 1.5 1.0 1.0 0.5 0.5 0.5 - - - Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 14: Significant growth in subscription revenue
Q 1 2 Significant growth in subscription revenue Subscription revenue and % of total revenue 90% 3.5 80% 80% 78% 3.0 75% 72% 72% 71% 70% 70% 68% 2.5 60% 60% 54% 2.0 50% 44% 40% 1.5 30% 1.0 22% 23% 20% 16% 0.5 10% 0% - Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Subscripti
Slide 15: Adjusted EBITDA
Q 1 2 Adjusted EBITDA 4.5 EBITDA by division 4 3.5 1.3 49% 1.0 Q1 2024 0.1 6% 3 (0.3) 2.5 1.1 2 1.2 49% 1.5 1.0 14% Q1 2023 0.1 4% 1 (0.3) 0.5 1.1 0.9 0 (0.4) (0.2) - 0.2 0.4 0.6 0.8 1.0 1.2 1.4 2023 ADJ EBITDA 2024 ADJ EBITDA Lifecare Wel lness Group Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1
Slide 16: Cashflow
Q Cashflow 1 2 3.0 Available liquidity €2.7m 2.5 2.0 (0.0) €2.1m undrawn on 2.1 (0.1) 1.5 facility 1.1 (0.8) 1.0 (0.1) 0.00 0.5 0.5 0.6 - 1 Jan 2024 Opening Net Adjusted EBITDA Working capital Interest expense Purchase of intangibles Adjusting it ems Fx 31 March 2024 Closing net cash cash 16 Q1 Q2 Q
Slide 17: Positive free cash-flow generating for a successive quarter
Q 1 2 Positive free cash-flow generating for a successive quarter 0.4 0.2 - Q122 Q222 Q322 Q422 Q123 Q223 Q323 Q423 Q124 (0.2) (0.4) (0.6) (0.8) (1.0) (1.2) (1) Free cash flow is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipment and f
Slide 18: Balance sheet
Q 1 2 Balance sheet 31 March 2024 31 March 2023 Euros '000 Goodwill, intangibles and PPE 34,237 37,637 Cash and cash equivalents 590 726 Borrowings (3,645) (3,019) Trade and other receivables 3,534 3,002 Trade and other payables (2,331) (2,162) Deferred revenue (2,149) (1,872) Deferred tax (1,134) (
Slide 19: Strategy and outlook
Strategy and outlook Q1 Q2 Q3 Q4 19 1
Slide 20: Our unique value proposition
Our unique value proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes, through more personalized, data-driven care Positioned to capitalize on grow
Slide 21: How it all comes together - investing in Physitrack
How it all comes together - investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Growing market supported Physitrack aims to achieve a doubling of 1. Market growth dynamics by underlying macro revenue within the medium term, replacing trends t
Slide 22: Q&A
Q&A Q1 Q2 Q3 Q4 22 2